A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Arcus Biosciences, Inc.
City of Hope Medical Center
Toray Industries, Inc
M.D. Anderson Cancer Center
AstraZeneca
Endocyte
National Cancer Institute (NCI)